Luke Hachfeld
Family · Mason City, IANPI 1326417577
Payments from drug & device makers
Across 160 payments — averaging $15.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$846
- AbbVie$381
- Novo Nordisk$303
- E.r. Squibb & Sons, L.L.C.$130
- Lilly USA, LLC$119
- Boehringer Ingelheim$115
- plus $614 from 17 others
What the payments were for
- Food & beverage$2,508100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 60 | $846 |
| AbbVie | 28 | $381 |
| Novo Nordisk | 16 | $303 |
| E.r. Squibb & Sons, L.L.C. | 7 | $130 |
| Lilly USA, LLC | 9 | $119 |
| Boehringer Ingelheim | 6 | $115 |
| AstraZeneca | 6 | $102 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $71 |
| GSK | 4 | $60 |
| Amgen | 3 | $46 |
| Phathom Pharmaceuticals, Inc. | 2 | $44 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $35 |
| Biohaven Pharmaceuticals, Inc. | 2 | $33 |
| Teva Pharmaceuticals USA, Inc. | 2 | $32 |
| Harmony Biosciences LLC | 1 | $29 |
| Vertex | 1 | $29 |
| Merck | 2 | $28 |
| Novartis | 1 | $23 |
| Bayer | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Ironshore Pharmaceuticals Inc. | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| Genentech USA, Inc. | 1 | $10 |
How this compares
$2,508 in reported general payments places this provider in the 90th percentile of 1,268 family providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 74 | $84,724 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 32 | $48,155 |
| EliquisApixaban | 51 | $40,503 |
| JardianceEmpagliflozin | 37 | $39,460 |
| FarxigaDapagliflozin Propanediol | 41 | $31,654 |
| TrulicityDulaglutide | 23 | $28,735 |
| DescovyEmtricitabine/Tenofov Alafenam | 12 | $27,918 |
| UbrelvyUbrogepant | 24 | $27,820 |
| RybelsusSemaglutide | 14 | $26,364 |
| VraylarCariprazine Hcl | 13 | $18,437 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 18 | $16,355 |
| MounjaroTirzepatide | 15 | $15,768 |
| LinzessLinaclotide | 21 | $13,178 |
| GlyxambiEmpagliflozin/Linagliptin | 15 | $12,962 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 26 | $12,492 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimSynjardy Xr, Jardiance, Glyxambi, Stiolto Respimat, Spiriva Respimat | $115 | $123,596130 claims |
| Novo NordiskOzempic, Rybelsus | $303 | $111,08888 claims |
| AbbVieUbrelvy, Vraylar, Linzess | $381 | $59,43458 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $102 | $48,00959 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $119 | $44,50338 claims |
| PfizerEliquis | $846 | $40,50351 claims |
| GSKTrelegy Ellipta | $60 | $12,02219 claims |
| MerckBelsomra | $28 | $6,30715 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,268 family providers in Iowa.
Other family in Mason City
- Michael GerberMason City$6K
- Kaci YoungerMason City$4K
- Krishna HughesMason City$4K
- Stefanie GaticaAnkeny$354K
- Aubrey MolgaardAmes$238K
- Joan KittenFort Dodge$85K
- Megan FergusonPella$82K
- Rodney ClarkDes Moines$63K
- Jennifer CondonFort Dodge$31K
- Karen HunkeAmes$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.